Compare CVR & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVR | BIVI |
|---|---|---|
| Founded | 1920 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4M | 14.2M |
| IPO Year | N/A | N/A |
| Metric | CVR | BIVI |
|---|---|---|
| Price | $12.23 | $1.42 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.1K | ★ 60.7K |
| Earning Date | 11-07-2025 | 11-10-2025 |
| Dividend Yield | ★ 0.84% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $26,008,045.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.15 | $1.25 |
| 52 Week High | $17.26 | $27.00 |
| Indicator | CVR | BIVI |
|---|---|---|
| Relative Strength Index (RSI) | 78.71 | 42.45 |
| Support Level | $10.01 | $1.45 |
| Resistance Level | $11.00 | $1.63 |
| Average True Range (ATR) | 0.61 | 0.09 |
| MACD | 0.54 | 0.02 |
| Stochastic Oscillator | 94.13 | 35.90 |
Chicago Rivet & Machine Co is in the fastener industry in North America. The company operates in two segments namely fasteners and assembly equipment. Its fastener segment consists of the manufacture and sale of rivets, cold-formed fasteners, parts, and screw machine products. The assembly equipment segment consists mainly of the manufacture of automatic rivet setting machines, automatic assembly equipment, and parts and tools for such machines. The majority of revenue is from the fastener segment.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.